Research Article
XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up
Table 3
Clinical characteristics of the study group.
| Characteristic | N | % | Median (Q1; Q3) | Range |
| BCVA change in the combined procedure group, n (%) | Decline | 1/10 | 10 | | | No change | 1/10 | 10 | | | Increase | 8/10 | 90 | | |
| BCVA change in the solo procedure group, n (%) | Decline | 12/59 | 20.3 | | | No change | 13/59 | 22.0 | | | Increase | 34/59 | 57.6 | | |
| IOP change, n (%) | Decline | 49/64 | 76.6 | | | No change | 5/64 | 7.8 | | | Increase | 10/64 | 15.6 | | | Decline ≥ 20% | 9/64 | 14.1 | | | Decline < 20% | 40/64 | 62.5 | | | IOP final level ≤ 15 mmHg | 31/64 | 48.4 | | | Massage recommendation, n (%) | 13/72 | 18.0 | | | Needling, n (%) | 43/64 | 67.2 | | | Number of needling procedures | 43 | | 2.00 (1.50; 3.00) | 1–12 | Number of drugs before surgery | 67 | | 4.00 (3.00; 5.00) | 1–5 | Time to inclusion of first drug, days | 54 | | 49.50 (20.50; 137.50) | 0–764 | Final number of drugs | 67 | | 2.00 (1.00; 4.00) | 0–4 | Complications, n (%) | 23/69 | 33.3 | | | Reoperations, n (%) | 17/71 | 23.9 | | |
|
|
Combined procedure: XEN implantation with phacoemulsification; solo procedure: XEN implantation.
|